JP2018515460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515460A5 JP2018515460A5 JP2017555626A JP2017555626A JP2018515460A5 JP 2018515460 A5 JP2018515460 A5 JP 2018515460A5 JP 2017555626 A JP2017555626 A JP 2017555626A JP 2017555626 A JP2017555626 A JP 2017555626A JP 2018515460 A5 JP2018515460 A5 JP 2018515460A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- use according
- pain
- inflammatory
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims 4
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims 2
- -1 1,1,1,3,3,3-hexafluoropropan-2-yl Chemical group 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 230000003639 vasoconstrictive effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158088A JP2022008597A (ja) | 2015-05-11 | 2021-09-28 | 炎症または神経障害性疼痛を処置する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562159770P | 2015-05-11 | 2015-05-11 | |
| US62/159,770 | 2015-05-11 | ||
| US201662297670P | 2016-02-19 | 2016-02-19 | |
| US62/297,670 | 2016-02-19 | ||
| PCT/US2016/031668 WO2016183097A1 (en) | 2015-05-11 | 2016-05-10 | Methods of treating inflammation or neuropathic pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158088A Division JP2022008597A (ja) | 2015-05-11 | 2021-09-28 | 炎症または神経障害性疼痛を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515460A JP2018515460A (ja) | 2018-06-14 |
| JP2018515460A5 true JP2018515460A5 (enExample) | 2019-06-13 |
Family
ID=57249499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555626A Pending JP2018515460A (ja) | 2015-05-11 | 2016-05-10 | 炎症または神経障害性疼痛を処置する方法 |
| JP2021158088A Pending JP2022008597A (ja) | 2015-05-11 | 2021-09-28 | 炎症または神経障害性疼痛を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158088A Pending JP2022008597A (ja) | 2015-05-11 | 2021-09-28 | 炎症または神経障害性疼痛を処置する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10450302B2 (enExample) |
| EP (1) | EP3294731A4 (enExample) |
| JP (2) | JP2018515460A (enExample) |
| KR (1) | KR20180004263A (enExample) |
| CN (2) | CN107849021A (enExample) |
| AU (3) | AU2016262459A1 (enExample) |
| BR (1) | BR112017024253A2 (enExample) |
| CA (1) | CA2984480A1 (enExample) |
| EA (1) | EA201792496A1 (enExample) |
| HK (1) | HK1252658A1 (enExample) |
| IL (2) | IL255239A0 (enExample) |
| MX (2) | MX2017014344A (enExample) |
| SG (1) | SG10202012002TA (enExample) |
| WO (1) | WO2016183097A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508407A (ja) | 2012-01-06 | 2015-03-19 | アビデ セラピューティクス，インク． | カルバメート化合物およびその製造および使用 |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN107849021A (zh) | 2015-05-11 | 2018-03-27 | 阿比德治疗公司 | 治疗炎症或神经性疼痛的方法 |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| MA58133B1 (fr) * | 2016-11-16 | 2024-02-29 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| WO2018093950A1 (en) * | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| CA3155260A1 (en) * | 2019-09-26 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods for reducing rewarding effects of morphine without affecting its analgesic effects |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| MX2022013224A (es) * | 2020-04-21 | 2022-11-14 | H Lundbeck As | Sintesis de un inhibidor de la monoacilglicerol lipasa. |
| US20210369704A1 (en) * | 2020-05-29 | 2021-12-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity |
| EP4457213A4 (en) | 2021-12-29 | 2025-12-17 | Psy Therapeutics Inc | INHIBITION OF MONOACYLGLYCEROL LIPASE (MAGL) |
| CA3246171A1 (en) * | 2022-03-31 | 2023-10-05 | Mayo Foundation For Medical Education And Research | METHODS AND MATERIALS FOR THE TREATMENT OF PANCREATIC DISEASES AND DISORDERS |
| WO2023213854A1 (en) | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor. |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| DE69222847T3 (de) | 1991-04-16 | 2005-09-15 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung einer festen dispersion |
| CA2122479C (en) | 1991-11-22 | 1998-08-25 | Richard John Dansereau | Risedronate delayed-release compositions |
| WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| EP0665010B1 (en) | 1992-10-16 | 2002-09-11 | Nippon Shinyaku Company, Limited | Method of manufacturing wax matrices |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| AU1384795A (en) | 1993-12-22 | 1995-07-10 | Shell Internationale Research Maatschappij B.V. | Process for preparing carbamates |
| CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
| EP0863879A1 (en) | 1995-11-15 | 1998-09-16 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6503713B1 (en) | 1999-10-04 | 2003-01-07 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying RNA binding compounds |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| WO2003070247A1 (en) * | 2002-02-20 | 2003-08-28 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
| CA2556268A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| WO2006066914A2 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| MX336930B (es) | 2005-11-28 | 2016-02-05 | Marinus Pharmaceuticals | Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas. |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| AU2007337886C1 (en) | 2006-12-22 | 2014-10-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| EP2124927A2 (en) | 2007-02-26 | 2009-12-02 | Kosan Biosciences Incorporated | Carbamate compounds |
| FR2938341A1 (fr) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| AU2009270983A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as GPCR modulators |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| US8492397B2 (en) | 2009-03-23 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Aminopyridine derivatives having Aurora A selective inhibitory action |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| JP2013510203A (ja) | 2009-11-03 | 2013-03-21 | バイエル・マテリアルサイエンス・アクチェンゲゼルシャフト | 感光性ポリマー組成物における添加剤としてのフルオロウレタン |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| JP2015508407A (ja) | 2012-01-06 | 2015-03-19 | アビデ セラピューティクス，インク． | カルバメート化合物およびその製造および使用 |
| AU2013207289B2 (en) | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| CA2866302A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| WO2013159095A1 (en) * | 2012-04-20 | 2013-10-24 | Anderson Gaweco | Ror modulators and their uses |
| FI2914248T4 (fi) | 2012-11-02 | 2023-12-19 | Vertex Pharma | Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| WO2015179559A2 (en) | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN107849021A (zh) | 2015-05-11 | 2018-03-27 | 阿比德治疗公司 | 治疗炎症或神经性疼痛的方法 |
| WO2018093950A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| MA58133B1 (fr) | 2016-11-16 | 2024-02-29 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2016
- 2016-05-10 CN CN201680040975.4A patent/CN107849021A/zh active Pending
- 2016-05-10 KR KR1020177035499A patent/KR20180004263A/ko not_active Ceased
- 2016-05-10 HK HK18111965.8A patent/HK1252658A1/zh unknown
- 2016-05-10 SG SG10202012002TA patent/SG10202012002TA/en unknown
- 2016-05-10 JP JP2017555626A patent/JP2018515460A/ja active Pending
- 2016-05-10 WO PCT/US2016/031668 patent/WO2016183097A1/en not_active Ceased
- 2016-05-10 US US15/573,272 patent/US10450302B2/en not_active Expired - Fee Related
- 2016-05-10 MX MX2017014344A patent/MX2017014344A/es unknown
- 2016-05-10 EA EA201792496A patent/EA201792496A1/ru unknown
- 2016-05-10 EP EP16793377.9A patent/EP3294731A4/en not_active Withdrawn
- 2016-05-10 CN CN202110689840.3A patent/CN113413387A/zh active Pending
- 2016-05-10 CA CA2984480A patent/CA2984480A1/en not_active Abandoned
- 2016-05-10 AU AU2016262459A patent/AU2016262459A1/en not_active Abandoned
- 2016-05-10 BR BR112017024253A patent/BR112017024253A2/pt not_active Application Discontinuation
-
2017
- 2017-10-24 IL IL255239A patent/IL255239A0/en unknown
- 2017-11-08 MX MX2021014815A patent/MX2021014815A/es unknown
-
2019
- 2019-09-06 US US16/563,733 patent/US11034674B2/en not_active Expired - Fee Related
-
2020
- 2020-08-07 AU AU2020213382A patent/AU2020213382A1/en not_active Abandoned
-
2021
- 2021-04-09 US US17/227,072 patent/US20210230145A1/en not_active Abandoned
- 2021-06-22 IL IL284299A patent/IL284299A/en unknown
- 2021-09-28 JP JP2021158088A patent/JP2022008597A/ja active Pending
-
2022
- 2022-05-25 AU AU2022203543A patent/AU2022203543A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515460A5 (enExample) | ||
| CN110139865A (zh) | Fgfr抑制剂 | |
| CN111683928A (zh) | 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 | |
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| CN110352188A (zh) | 氟代烯丙胺衍生物及其用途 | |
| CN115667238A (zh) | 一种五并五元环衍生物及其在医药上的应用 | |
| JP2020502047A5 (enExample) | ||
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2015508749A5 (enExample) | ||
| JP2015120736A5 (enExample) | ||
| JP2017505285A5 (enExample) | ||
| CN112867717A (zh) | 用作激酶抑制剂的化合物及其应用 | |
| CN115315427A (zh) | Hpk1抑制剂及其制备方法和用途 | |
| JP2017503798A5 (enExample) | ||
| JP2014062126A5 (enExample) | ||
| JP2012255002A5 (enExample) | ||
| CN110072865A (zh) | 吡咯并芳杂环类化合物及其制备方法和医药用途 | |
| JP2019516739A5 (enExample) | ||
| CN113939514A (zh) | 吡咯并嘧啶类化合物及其应用 | |
| JP2017538712A5 (enExample) | ||
| CN115776983A (zh) | 杂环类免疫调节剂 | |
| CN109563082A (zh) | 核磁共振显像化合物、其中间体、核磁共振显像剂及应用、以及核磁共振成像方法 | |
| CN113825755A (zh) | 作为irak4抑制剂的咪唑并吡啶类化合物 | |
| CN109563051A (zh) | 作为pde4抑制剂的并环类化合物 | |
| JP2007530703A5 (enExample) |